Lobbying Filing Details
Total Spending
$60,000
Activities
2
Lobbyists
2
Gov't Entities
6
Filing Information
- Filing UUID:
83ae19af-acdf-42b5-9dfd-3f534dc0dfe3- Type:
- Q2 - 2nd Quarter - Report
- Period:
- 2026 - 2nd Quarter (Apr 1 - June 30)
- Date Posted:
- July 20, 2026 at 2:50 PM
- Income:
- $60,000
- Expenses:
- $0
- Document URL:
- View Submission
Quick Info
- Document Type: text/html
- Posted By: Megan Herber
Registrant
FAEGRE DRINKER BIDDLE & REATH LLP
Law firm
Washington, District of ColumbiaClient
TEVA PHARMACEUTICALS USA, INC.
Pharmaceutical manufacturer
New Jersey, United States of AmericaLobbying Activities (2)
Activity 1
Copyright/Patent/TrademarkSkinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Lobbyists (2)
- MEGAN SUSSMAN HERBER
- MR. ELLIOT VICE
Government Entities (3)
- SENATE
- HOUSE OF REPRESENTATIVES
- Health & Human Services, Dept of (HHS)
Activity 2
Health IssuesSkinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Lobbyists (2)
- MEGAN SUSSMAN HERBER
- MR. ELLIOT VICE
Government Entities (3)
- SENATE
- HOUSE OF REPRESENTATIVES
- Health & Human Services, Dept of (HHS)